Available Technologies

Browse Penn-owned technologies available for licensing.


Mouse Model of Gastric Cancer


Rapid, novel mouse model of gastric cancer with metastasis 



Sandra Ryeom Ph.D., Department of Cancer Biology


Technology Overview

UPenn investigators developed a model of mixed type gastric cancer results from combinatorial conditional loss of the Cdh1 (E-cadherin), and p53 genes, and acquisition of expression of oncogenic Kras in gastric parietal cells. Mice exhibit significant disease related morbidity at a median of 77 days of age. Upon gross examination at necropsy 100% of mice present with enlarged, thickened, and whitened stomachs (linea plastic), epigastric lymph node metastases (100%) and mediastinal lymph node metastases (50%). Upon microscopic evaluation the primary tumors were characterized as mixed type gastric cancer containing >25% diffuse type cells. Microscopic observation confirmed the metastatic lesions through the use of the conditional YFP reporter allele (also present in the model) and further identified lung metastases in 100% of mice and liver metastases in 20% of mice.

robust signal to noise and great potential for improving gene/cell immunotherapy.



• Rapid model of gastric cancer

• 100% penetrance

• Easy to follow disease progression using mouse weight

• Metastasis development that recapitulates progression of human cancer

• Metastasis development in 100% of mice

• Conditional expression of YFP reporter in tumor tissue for tracking of metastatic phenotype



• Drug screening

• Drug validation

• Metastasis Studies

• Microbiome Studies